1. Please check and comment entries here.
Table of Contents

    Topic review

    Antioxidants and Human Oocyte Mitochondrial


    Mitochondria produce adenosine triphosphate (ATP) while also generating high amounts of reactive oxygen species (ROS) derived from oxygen metabolism. ROS are small but highly reactive molecules that can be detrimental if unregulated. While normally functioning mitochondria produce molecules that counteract ROS production, an imbalance between the amount of ROS produced in the mitochondria and the capacity of the cell to counteract them leads to oxidative stress and ultimately to mitochondrial dysfunction. This dysfunction impairs cellular functions through reduced ATP output and/or increased oxidative stress. Mitochondrial dysfunction may also lead to poor oocyte quality and embryo development, ultimately affecting pregnancy outcomes. Improving mitochondrial function through antioxidant supplementation may enhance reproductive performance. Recent studies suggest that antioxidants may treat infertility by restoring mitochondrial function and promoting mitochondrial biogenesis. Antioxidant properties of coenzyme-Q10, resveratrol, melatonin and several vitamins have been evaluated in the human oocyte, although their direct action on mitochondrial function has yet to be elucidated.

    1. Introduction 

    Mitochondria produce the energy required by cells to carry out all cellular processes. Energy is generated in the form of adenosine triphosphate (ATP) through oxidative phosphorylation, a process that takes place in the inner mitochondrial membrane under aerobic conditions. Along this membrane, electrons from the controlled oxidation of nicotinamide adenine dinucleotide (NADH) or flavin adenine dinucleotide (FADH2), both products of the citric acid cycle, travel through several enzymatic complexes forming the electron transport chain (ETC). The movement of electrons throughout the ETC is coupled with the transfer of protons across the membrane into the intermembrane space, generating an electrochemical proton gradient over the inner mitochondrial membrane that is harnessed by F1-F0 ATPase to phosphorylate adenosine diphosphate (ADP) into ATP [1] (Figure 1).

    Figure 1. Production of adenosine triphosphate (ATP) by oxidative phosphorylation coupled to the mitochondrial electron transport chain. The four enzymatic complexes (I, II, III, and IV) and ATP synthase are represented in the inner mitochondrial membrane. ADP: adenosine diphosphate; ATP: adenosine triphosphate; Pi: inorganic phosphate; H+: hydrogen ion (proton); NADH: nicotinamide adenine dinucleotide, reduced form; FADH2: flavin adenine dinucleotide, reduced form; NAD+: nicotinamide adenine dinucleotide, oxidized form; FAD: flavin adenine dinucleotide, oxidized form; O2: oxygen; H2O: water; Cyt c: cytochrome c; CoQ10: coenzyme-Q10.

    Mitochondrial respiration is a form of aerobic metabolism and uses oxygen to produce energy, with oxygen as the ultimate electron acceptor of the electron flow system of the mitochondrial ETC. However, mitochondrial electron flow may become uncoupled at several sites along the chain, resulting in unpaired single electrons that react with oxygen or other electron acceptors and generate free radicals. When these electrons react with oxygen, the resulting free radicals are referred to as reactive oxygen species (ROS). These include the superoxide anion (O2•−), which forms hydrogen peroxide (H2O2) and can further react to form the hydroxyl radical (HO). Unrelated to respiration, there is also a large source of H2O2 in the outer mitochondrial membrane due to monoamine oxidase catalytic activity [1][2].

    Physiological levels of ROS are required for normal cellular function [3]. However, ROS are also highly reactive molecules that can damage mitochondrial components, initiate degradative processes, deregulate essential cellular functions, and initiate many pathological conditions if generated uncontrollably [1]. Therefore, many organisms have developed a system of antioxidant defense, in which mitochondria play a major role as antioxidant producers, allowing them to maintain balanced levels of oxidants and antioxidants [3]. An antioxidant is any substance that delays the oxidation of lipids, carbohydrates, proteins, or DNA by directly scavenging ROS or by indirectly up-regulating antioxidant defenses or inhibiting ROS production. There are many different endogenous and exogenous sources of antioxidants [3][4], but the first line of defense is also the main ROS producer in the cell: the mitochondria.

    Antioxidants counteract the high levels of ROS derived from mitochondrial metabolism, reducing damage to the cell. However, an imbalance between the amount of antioxidants and ROS produced, in favor of the latter, leads to oxidative stress [3]. Oxidative stress generates lipid peroxidation [5], as well as RNA, DNA, and protein oxidation, which in turn leads to their selective enzymatic degradation by nucleases and proteases [2]. On the one hand, lipid peroxidation affects the integrity of cell membranes [5]. On the other hand, nuclear DNA degradation induces the onset of apoptosis [6] and occurs at the same time as the release of mitochondrial cytochrome c (Cyt c) [2], which is also responsible for the initiation of programmed cell death [7]. Oxidative stress may also interfere with essential mitochondrial functions within the cell by promoting the inactivation of enzymes from the mitochondrial ETC [8] and by increasing mtDNA mutations. In fact, mitochondrial DNA is prone to mutations because it lacks protective histones and is in close proximity to the inner mitochondrial membrane [9]. Finally, oxidative stress has also been related to telomere shortening and senescence [10].

    Oxidative stress can be caused by, or be the cause of, mitochondrial dysfunction (MD). MD reduces the production of ATP and synthesis of antioxidant molecules, creating a cycle in which ROS-induced mitochondrial damage results in higher oxidant production and further mitochondrial impairment [11]. MD is involved in the pathogenesis of many neurodegenerative and cardiovascular diseases, such as Alzheimer's disease and atherosclerosis [12][13]. In the reproductive field, MD is related to a decline in oocyte quality [14]. Mitochondria are essential organelles involved in meiotic spindle assembly, proper segregation of chromosomes, maturation, fertilization, and embryo development [15]. Therefore, MD may affect the quality and DNA content of oocytes, embryo development, and pregnancy outcome. The consequences of MD are not limited to the short-term, as oxidative stress exposure during the gestational period is related to long-lasting cardiovascular effects [16].

    Regardless of origin, oxidative stress and MD are triggered by both intrinsic and extrinsic factors. Intrinsic factors include biological age [11][17], endometriosis [18], polycystic ovarian syndrome (PCOS) [19], and premature ovarian insufficiency (POI) [20]. Extrinsic factors include environmental exposure to ROS inducers or producers, such as diet, professional exposure, and assisted reproduction treatment (ART) techniques [21]. Some of these factors are modifiable and, therefore, offer opportunities for intervention.

    ROS are natural products of sperm, oocyte, and embryo metabolism. However, gamete manipulation during ART procedures increases ROS either through indirect intracellular ROS production in response to external stressors or through direct exogenous ROS production by environmental factors. The risk of oxidative stress development is higher in vitro than in vivo, although it remains unclear to what extent ART is responsible for higher levels of oxidative stress [21]. Despite recent advancements in ART techniques [22][23][24][25], the in vitro fertilization (IVF) setting does not recreate the conditions of natural fertilization, which includes tight physiological regulation of oxidative stress by antioxidants. Oxygen concentration, temperature variation, high light exposure, culture media composition, and cryopreservation methods are environmental sources of oxidative stress in the IVF laboratory [21], implicating the need for antioxidant supplementation in the IVF setting. Indeed, human IVF culture media are supplemented with combinations of molecules with antioxidant properties, including human serum albumin, ethylenediaminetetraacetic acid, folic acid, ascorbic acid, and pantothenic acid (vitamin B5), among others [25].

    Antioxidants are endogenous to organisms, but it is uncertain if supplementation of these substances can improve oocyte mitochondrial function. Although several supplementary antioxidant molecules have shown promising results [26][27][28], two recent Cochrane reviews described low-quality evidence about the positive effects of oral antioxidant treatment in live birth and clinical pregnancy rates in women attending an infertility clinic [29][30]. In this entry we focus on the role of coenzyme-Q10, resveratrol, melatonin and several vitamins. Figure 2 presents a graphic representation of their antioxidant properties.

    Figure 2. Antioxidant properties of the molecules reviewed (coenzyme-Q10, resveratrol, melatonin, and vitamins A, B, C, and E).

    2. Antioxidant Supplementation in Reproduction

    Antioxidant treatment in the reproductive field can be carried out either by oral supplementation before infertility treatment or by culture media supplementation during ART. Oral supplementation attempts to improve gamete quality in vivo, while culture media supplementation attempts to do so in vitro. The latter approach can also be used to improve the in vitro maturation (IVM) process and to counteract high ROS production within the IVF setting.

    Antioxidant supplementation is generally described in the literature as being applied to the male [31]. In this review, we discuss the use of antioxidants to improve oocyte and embryo quality, both in vivo and in vitro. We focus on mitochondrial function because its enhancement may be the main mechanism by which antioxidants manage to improve gamete quality. However, although mitochondrial function has been restored by different antioxidant molecules in many other tissues [32][33][34][35], this direct association has not yet been demonstrated in the human oocyte. A summary of the main evidence regarding the current utility of each of the antioxidants described is presented in Table 1, while a more extensive summary of the results of the discussed human studies is presented in Table 2.

    Table 1. Brief summary of evidence from published studies on the utility of the antioxidants reviewed. Only human studies are summarized. A green tick means that at least one study found beneficial effects on oocyte/embryo quality; a red cross means that the studies reviewed did not find any beneficial effects; a question mark means that the antioxidant effect has not been studied in that scenario.

    Table 2. Summary of clinical trials conducted to evaluate antioxidant supplementation protocols in vitro and in vivo to improve oocyte quality. p-values > 0.05 are presented as p = NS (non-significant). Gr.: group. RCT: randomized controlled trial. y.o.: years old. CPR: clinical pregnancy rate. MR: miscarriage rate. LBR: live birth rate. GV: germinal vesicle. OR: odds ratio. CI: confidence interval. IVM: in vitro maturation. hCG: human chorionic gonadotropin. MII: metaphase II. IVF: in vitro fertilization.



    Type of Study

    In Vitro/In Vivo


    Primary Endpoint


    Treatment Groups (n)



    Bentov et al., 2014 [26]



    In vivo

    600 mg/day for 2 months until the day of oocyte retrieval.

    Double blinded.

    Number of euploid embryos per retrieval

    IVF patients 35-43 y.o.

    Study gr.: 17

    Control gr: 22

    Lower aneuploidy rate in the CoQ10 group (46.5% vs. 62.8% in the control group; p = NS). Premature termination of the study.

    El Refaeey et al., 2014 [36]


    In vivo

    60 mg three times per day from day 2 of cycle until the day of ovulation induction.


    Number of follicles >14 and ≥18 mm

    CC-resistant PCOS

    Study gr.: 51

    Control gr.: 50

    In the treatment group, higher number of follicles >14 mm (1.94 ± 0.25 vs. 0.13 ± 0.29; p < 0.05) and of follicles ≥18 mm (1.85 ± 0.27 vs. 1.30 ± 0.32; p < 0.001).

    Xu et al., 2018 [37]


    In vivo

    600 mg/day for 60 days before the initiation of ovarian stimulation

    Number of high-quality day-3 embryos

    Poor ovarian response patients <35 y.o.

    Study gr.: 76

    Control gr.: 93

    Higher mean number of good quality day-3 embryos in the CoQ10 group (1 vs. 0 in the control group; p = 0.03).

    Secondary endpoints:

    - Higher ovarian response in the CoQ10 group (4 vs. 2 mean retrieved oocytes; p = 0.002).

    - Higher fertilization rate in the CoQ10 treatment group (67.5% vs. 45.1%; p = 0.001).

    - No significant differences in CPR, MR, and LBR.


    Ma et al., 2020 [38]


    In vitro

    IVM medium supplemented with 50 mmol/L for 24 h

    Oocyte maturation and postmeiotic aneuploidy rates

    IVM of GV from patients ≥38 y.o. and patients ≤30 y.o.

    45 patients ≥38 y.o.

    Study gr.: 46GV

    Control gr.: 46GV

    18 patients ≤30 y.o.

    Study gr.: 35GV

    Control gr.: 39GV

    Patients ≥38 y.o.:

    - Higher maturation rate in the CoQ10 group (82.6% vs. 63.0%; p = 0.035).

    - Reduced postmeiotic aneuploidy rate in the CoQ10 group (36.8% vs. 65.5%; p = 0.02).

    Patients ≤30 y.o.:

    - Similar maturation rates (80.0% in the CoQ10 group vs. 76.9% in the control group; p = 0.8).

    - Similar postmeiotic aneuploidy rates (28.6% in the CoQ10 group vs. 30.0% in the control group; p = 0.9).


    Kile et al., 2020 [39]


    Preliminary results (ASRM Congress 2020)

    In vitro

    Mitoquinol addition to the culture media from fertilization and throughout embryo development

    Effect on embryo development

    Advanced maternal age (≥35 y.o.) women

    11 patients

    Study gr: 66 embryos

    Control gr: 143 embryos

    No differences between control and Mitoquinol treatment in day 5 (18% in control group vs. 20% in the study group) or total (48% vs. 45%) good quality blastocyst development per zygote, total blastocyst development (63% vs. 62%) and euploidy rates (33% vs. 30%); p = NS.


    Liu et al., 2018 [40]


    In vitro

    IVM medium supplemented with 1.0 µm for 24 and 36 h

    Maturation rates after 24 and 36 h, mitochondrial immunofluores-cence intensity, and proportion of matured oocytes with an abnormal spindle morphology and irregular chromosomal arrangement

    IVM of GV from patients 38-45 y.o.

    64 patients

    Study gr.: 38GV

    Control gr.: 37GV

    - Increased maturation rates of the resveratrol group after 24 h (55.3% vs. 37.84% in the control group; p < 0.05) and 36 h (71.1% vs. 51.35%; p < 0.05) of IVM culture.

    - Increased mitochondrial immunofluorescence intensity in the resveratrol group (53.0% vs. 31.1%, p < 0.05).

    - Reduced proportion of abnormal spindle morphology and irregular chromosomal arrangement in the resveratrol group (p < 0.05).

    Bahramrezaie et al., 2019 [41]


    In vivo

    800 mg/day for 40 days until the day of oocyte retrieval.

    Triple blinded.

    Levels of VEGF expression in granulosa cells

    Infertile PCOS patients 18-40 y.o.

    Study gr.: 30

    Control gr.: 31

    - Reduced VEGF expression in the resveratrol group (p = 0.0001).

    Secondary endpoints:

    - No differences between both groups in the number of mature oocytes and cleavage and fertilization rates (p = NS).

    - Higher high-quality oocyte rate (81.9% vs. 69.1%; p = 0.002) and high-quality embryo rate in the resveratrol group (89.8% vs. 78.8%; p = 0.024).


    Ochiai et al., 2019 [27]


    In vivo

    200 mg/day during the IVF cycle.

    Pregnancy outcomes (CPR and MR)

    IVF patients

    Study gr.: 204 cycles/102 women

    Control gr.:7073 cycles/2958 women

    Decreased CPR [10.8% vs. 21.5%; p = 0.0005 (Adjusted OR 95% CI 0.539, 0.341–0.853] and increased MR [52.4% vs. 21.8%; p = 0.0022 (Adjusted OR 95% CI 2.602, 1.070–6.325] after resveratrol supplementation.



    Takasaki et al., 2003 [42]

    Prospective cohort study with an intrapatient retrospective comparison

    In vivo

    1 or 3 mg/day from the fifth day of the previous cycle until the day of ovulation induction

    To compare oocyte quality between the previous and current IVF cycles

    Women with a previous IVF failure due to poor oocyte quality

    Study gr. (1 mg): 13

    Control gr.: previous cycle data.

    Study gr. (3 mg): 23

    Control gr.: previous cycle data.

    - Reduced number of degenerated oocytes in the 3 mg group (p < 0.05) vs. the control group.

    - Tendency toward an increased fertilization rate in the 3 mg group.

    - No differences in the numbers of retrieved and mature oocytes between the 3 mg and the control group.

    - No differences in the number of retrieved, mature, degenerated, and fertilized oocytes between the 1 mg and control group.

    Tamura et al., 2008 [43]

    Prospective cohort study with a retrospective comparison in the same population

    In vivo

    3 mg/day from the fifth day of the previous cycle until the day of oocyte retrieval

    To compare fertilization rates between the previous and current IVF cycles

    Women with a previous IVF failure due to low fertilization rate (≤50%)

    Study gr.: 56

    Control gr.: previous cycle data

    Placebo gr.: 59

    Control gr.: previous cycle data

    Increased fertilization rate in the melatonin group (29.8 points compared to the previous IVF cycle; p < 0.01), while there were no differences in the placebo group (1.9 points compared to the previous IVF cycle; p > 0.01).

    Eryilmaz et al., 2011 [28]


    In vivo

    3 mg/day from the third or fifth day of the previous cycle until the day of oocyte retrieval

    Oocyte quality

    IVF patients

    Study gr.: 30

    Control gr.: 30

    - Increased number of mature oocytes (9.0 vs. 4.4; p = 0.0001) in the treated group.

    Secondary endpoints:

    - Increased number of retrieved oocytes (11.5 vs. 6.9; p = 0.0001) in the treated group.

    Batıoğlu et al., 2012 [44]


    In vivo

    3 mg/day during the IVF cycle

    Number of MII oocytes

    IVF patients

    Study gr.: 40

    Control gr.: 45

    - No differences in the mean number of MII oocytes retrieved (12.0 in the study vs. 10.9 in the control gr.; p = 0.139).

    - Higher percentage of MII oocytes/retrieved in the treated group (81.9% in the study vs. 75.8% in the control gr.; p = 0.034).



    Kim et al., 2013 [45]


    In vitro

    IVM medium supplemented with 10 µmol/L for 24 and 48 h

    Maturation rates

    IVM of GV from PCOS patients with or without hCG priming during unstimula-ted cycles

    Study gr.: 62

    (41 non-hCG primed, 21 hCG primed)

    Control gr.: 49

    (25 non-hCG primed, 24 hCG primed)

    - In the non-hCG priming gr., there were no differences in the maturation rate between melatonin treatment and the control gr. after 24 h (40.0% vs. 40.0%; p = NS) and 48 h (62.5% vs. 60.3%; p = NS) of maturation.

    - In the hCG priming gr., there were no differences in the maturation rate between melatonin treatment and control gr. after 24 h (51.3% vs. 44.9%; p = NS) and 48 h (59.8% vs. 54.8%; p = NS) of maturation.

    Fernando et al., 2018 [46]


    In vivo

    2/4/8 mg/twice per day during ovarian stimulation.

    Double blind.


    IVF patients

    Study gr. (2 mg): 41

    Study gr. (4 mg): 39

    Study gr. (8 mg): 40

    Control gr.: 40

    - No differences in CPR (15% in the control group vs. 26.8 in the 2 mg group; 15.4 in the 4 mg group; 22.5 in the 8 mg group; p = 0.5).

    Secondary endpoints:

    - No differences in the total oocyte number (p = 0.8), number of MII oocytes (p = 0.4), number of fertilized oocytes (p = 0.6) and the number (p = 0.6) or quality (p = 0.9) of embryos between any of the three treatment groups and the control group.

    Espino et al., 2019 [47]


    In vivo

    3 or 6 mg/day from the onset of ovarian stimulation until the day of oocyte retrieval

    - TAC, SOD, and LPO as antioxidant markers in the follicular fluid.

    - 8-OHdG as oxidative stress marker in the follicular fluid.

    - IVF success.

    IVF patients with unexplained infertility

    Study gr. (placebo): 10

    Study gr. (3 mg): 10

    Study gr. (6 mg): 10

    Non-randomized control gr. (fertile women): 10

    - Restored concentrations of TAC, SOD, LPO, and 8-OHdG in the follicular fluid of the study gr. to levels found in fertile women (except for SOD levels in the 3 mg study gr.).

    - Improved MII oocyte rate (83.6% in the 3 mg gr. vs. 81.9 in the fertile gr., p = NS, and in comparison to 70.6 in the no-treatment gr., p < 0.05).

    - Improved MII oocyte rate (76.2% in the 6 mg gr., vs. 81.9% in the fertile gr. and 70.6% in the no-treatment gr.; p = NS).

    - Increased number of transferable embryos (5.1 in the 3 mg gr. and 4.6 in the 6 mg gr.; vs. 2.3 in the fertile gr., p < 0.05, and 2.0 in the no-treatment gr., p < 0.05).


    Folic acid

    Gaskins et al., 2014 [48]

    Prospective cohort

    In vivo

    Validated food frequency questionnaire, with specific data about supplemental folic acid intake

    To assess the relationship between pregnancy outcomes (implantation rate, CPR, and LBR) and supplemental folate intake

    Infertile IVF patients

    Total n: 232

    Quartile 1 (Q1)

    Folic acid <400 µg/day): 51

    Quartile 4 (Q4)

    Folic acid >800 µg/day): 60

    - Higher implantation rates [Adjusted mean; A.m., 95% CI 0.67 (0.56,0.77) vs. 0.43 (0.31, 0.55)], CPR [A.m., 95% CI 0.62 (0.51, 0.73) vs. 0.41 (0.29, 0.53)], and LBR [A.m., 95% CI 0.55 (0.43, 0.66) vs. 0.35 (0.24, 0.48)], in the Q4 in comparison to Q1 (p < 0.05).

    - Positive linear relationship between supplemental folate and LBR up to 1200 µg/day, without evidence of additional benefit with higher intakes.


    Murto et al., 2014 [49]

    Longitudinal cohort study

    In vivo

    Serum folate determinations (folate status) and folic acid supplement questionnaires (folic acid intake)

    CPR and LBR

    IVF patients with unexplained infertility

    Total n: 180

    [Serum folate]

    ≥22.5 nmol/L: 78/180

    <22.5 nmol/L: 89/180

    No data: 13


    Folic acid supplements intake

    Users: 137/180

    Non-users: 42/180

    No data: 1/180

    Folate status:

    - No statistically significant differences regarding CPR [35.9% when serum folate ≥22.5 nmol/L vs. 34.8%; OR 95% CI 0.954 (0.505–1.802)] and LBR [28.2% when serum folate ≥22.5 nmol/L vs. 27.0%; OR 95% CI 0.940 (0.476–1.855)].

    Folic acid intake:

    - No statistically significant differences regarding CPR [32.8% users vs. 35.7% non-users; OR 95% CI 1.003 (0.515–1.953)] and LBR [24.1% users vs. 31.0% non-users; OR 95% CI 1.366 (0.677–2.757)].


    Ascorbic acid

    Griesinger et al., 2002 [50]


    In vivo

    1/5/10 g/day from the day of oocyte retrieval and during the luteal phase (14 days).

    Double blind.

    Implantation rate and CPR

    Infertile IVF patients

    Study group (1g): 172

    Study group (5g): 153

    Study group (10g): 136

    Control gr.:158

    - Implantation rate was 10.0% in the 1 g group, 12.36% in the 5 g group, 10.3% in the 10 g group, and 14.8% in the control group (p = 0.186).

    - CPR was 22% in the 1 g group, 24% in the 5 g group, 21% in the 10 g group, and 28% in the control group (p = 0.186).

    Ascorbic acid

    Crha et al., 2003 [51]

    Prospective cohort

    In vivo

    500 mg/day during ovarian stimulation

    Number of pregnancies

    Infertile IVF patients

    Study gr.: 38

    Control gr.: 38

    No significant difference in the number of pregnancies (34.2% vs. 23.7% in the control group; p = NS).

    Lu et al., 2018 [52]


    In vivo

    1000 mg/day from 2 months before IVF treatment until 2 weeks after embryo transfer

    - Serum and follicular fluid levels of ascorbic acid.

    - Levels of oxidative stress markers

    Endometriosis patients

    Study gr.: 137

    Placebo gr.: 108

    - Higher serum and follicular fluid levels of ascorbic acid (levels not shown; p < 0.05) in the study group.

    - No difference in oxidative stress markers after treatment.

    Vitamin E


    Bahadori et al., 2017 [53]




    In vivo


    Serum and follicular fluid vitamin E determination


    To assess the relationship between serum and follicular fluid vitamin E levels and oocyte maturation and embryo quality


    IVF patients with a history of vitamin E supplementa-tion


    Total n: 50

    Follicular fluid ranges (mg/dL)








    Serum ranges (mg/dL) 1-5




    Follicular fluid:

    - Vitamin E levels within the ranges of 0.35-1 mg/dL and 1.5-2 mg/dL were related to higher oocyte maturation rates (89.2% and 84.9%, respectively, vs. 69.6% in 1-1.5 mg/dL and 76.7% in 2-7.4 mg/dL ranges; p = 0.002).

    - No significant relationship between vitamin E levels and embryo quality was observed.



    - Vitamin E levels between 10 and 15 mg/dL were correlated with a higher proportion of high-quality embryos (87.5% vs. 46.2 in 1-5 mg/dL, 54.9% in 5-10 mg/dL, 42.9% in 15-20 mg/dL; p = 0.007).

    - No significant relationship between vitamin E levels and oocyte maturation was observed.

    A higher proportion of MII oocytes in women with vitamin E supplementation (87.4% vs.77% in women without supplementation; p = 0.010).

    Antioxidants in combination

    Fatemi et al., 2017 [54]


    In vivo

    Vitamin E (400 mg/day) and Vitamin D (50,000 IU/one in two weeks) for 8 weeks.

    Double blinded.

    Implantation rate, pregnancy rate, and CPR

    PCOS infertile women

    Study gr.: 44

    Control gr.: 46


    Higher implantation (35.1% vs. 8.6%; p < 0.001), pregnancy (69.0% vs. 25.8%; p < 0.001), and CPR (62.1% vs. 22.6%; p = 0.002) in the treated group.


    Ozkaya et al., 2011 [55]


    In vivo

    Vitamins A,B,C,D, E, H; calcium; folic acid; iron; nicotinic acid; magnesium; phosphor; copper; manganese; zinc

    For 45 days before serum and follicular fluid collection

    Follicular fluid and serum antioxidant capacity

    IVF patients

    Study gr.: 26

    Placebo gr.: 30

    - Higher serum and follicular fluid antioxidant capacity were observed in the treated group.

    - Higher serum vitamins C (61.6 µmol/L vs. 57.9 µmol/L in the control group; p < 0.05) and A (2.3 µmol/L vs. 1.5 µmol/L; p < 0.01); and higher follicular fluid glutathione (0.4 µmol/L vs. 0.2 µmol/L; p < 0.01) and vitamin C (84.5 µmol/L vs. 52.7 µmol/L; p < 0.01) and E (8.3 µmol/L vs. 5.0 µmol/L; p < 0.001) concentrations.

    Youssef et al., 2014 [56]


    In vivo


    Vitamins A, E, C






    Number of MII oocytes

    IVF patients with unexplained infertility

    Study group: 112

    Control group: 106

    No difference in the mean number of MII oocytes between the treated (12.7) and the control group (13.2); p = 0.7.

    3. Conclusions

    Antioxidants are molecules that are easily obtained from natural sources. Their mechanisms of action are diverse, but they typically enhance mitochondrial function or directly scavenge free radicals, which in turn protects mitochondria and other cellular components from oxidative stress. Given the crucial role of mitochondrial activity in oocyte maturation, fertilization, and embryo development, antioxidants may improve ART outcomes by improving oocyte quality.

    In ART, antioxidant supplementation can be prescribed as an oral pre-treatment or as an adjuvant in the media during in vitro culture, although the extent of its effects have not been fully elucidated. Indeed, the majority of studies described throughout this review evaluate the indirect consequences of antioxidant supplementation on oocyte quality, evidenced by endpoints such as oocyte maturation, aneuploidy, and pregnancy rates, which may or may not be related to improved mitochondrial function. Although the direct relationship between antioxidant support and improved mitochondrial function is likely, further studies are needed to fully evaluate the consequence of antioxidant treatment on specific mitochondrial parameters, such as mitochondrial membrane potential, morphology, and distribution, as well as oxidative stress markers. In addition, there is no consensus on the optimal dose and duration of treatment, so further evaluation of these parameters is necessary before clinical application of antioxidant strategies.

    Although antioxidant therapy is a promising and safe therapy, well-designed human clinical trials are needed before it is incorporated into routine clinical practice. The population that can benefit from their use must also be clearly defined, and their short- and long-term safety must be evaluated. Further, the mechanisms of each antioxidant's action at the molecular level and the administration protocol must be clearly defined.

    This entry is adapted from 10.3390/antiox9121197


    1. Zhao, R.Z.; Jiang, S.; Zhang, L.; Yu, Z.-B. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int. J. Mol. Med. 2019, 44, 3–15, doi:10.3892/ijmm.2019.4188.
    2. Cadenas, E.; Davies, K.J.A. Mitochondrial Free Radical Generation, Oxidative Stress, and Aging. Free Radic. Biol. Med. 2000, 29, 222–230.
    3. Gulcin, İ. Antioxidants and antioxidant methods: An updated overview. Arch. Toxicol. 2020, 94, 651–715.
    4. Galano, A.; Reiter, R.J. Melatonin and its metabolites vs oxidative stress: From individual actions to collective protection. J. Pineal Res. 2018, 65, e12514.
    5. Ayala, A.; Muñoz, M.F.; Argüelles, S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev. 2014, 2014, doi:10.1155/2014/360438.
    6. Norbury, C.J.; Zhivotovsky, B. DNA damage-induced apoptosis. Oncogene 2004, 23, 2797–2808.
    7. Liu, X.; Kim, C.N.; Yang, J.; Jemmerson, R.; Wang, X. Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c. Cell 1996, 86, 147–157.
    8. Zhang, Y.; Marcillat, O.; Giulivi, C.; Ernster, L.; Davies, K.J.A. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J. Biol. Chem. 1990, 265, 16330–16336.
    9. Babayev, E.; Seli, E. Oocyte mitochondrial function and reproduction. Curr. Opin. Obstet. Gynecol. 2015, 27, 175–181.
    10. Passos, J.F.; Saretzki, G.; Von Zglinicki, T. DNA damage in telomeres and mitochondria during cellular senescence: Is there a connection? Nucleic Acids Res. 2007, 35, 7505–7513, doi:10.1093/nar/gkm893.
    11. Balaban, R.S.; Nemoto, S.; Finkel, T. Mitochondria, oxidants, and aging. Cell 2005, 120, 483–495.
    12. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443, 787–795.
    13. Di Lisa, F.; Kaludercic, N.; Carpi, A.; Menabò, R.; Giorgio, M. Mitochondria and vascular pathology. Pharmacol. Rep. 2009, 61, 123–130.
    14. May-Panloup, P.; Boucret, L.; de la Barca, J.M.C.; Desquiret-Dumas, V.; Ferré-L’Hotellier1, V.; Morinière, C.; Descamps, P.; Procaccio, V.; Reynier, P. Ovarian ageing: The role of mitochondria in oocytes and follicles. Hum. Reprod. Update 2016, 22, 725–743, doi:10.1093/humupd/dmw028.
    15. Wang, L.-Y.; Wang, D.H.; Zou, X.Y.; Xu, C.M. Mitochondrial functions on oocytes and preimplantation embryos. J. Zhejiang Univ. Sci. B 2009, 10, 483–492.
    16. Yang, H.; Kuhn, C.; Kolben, T.; Ma, Z.; Lin, P.; Mahner, S.; Jeschke, U.; von Schönfeldt, V. Early life oxidative stress and long-lasting cardiovascular effects on offspring conceived by assisted reproductive technologies: A review. Int. J. Mol. Sci. 2020, 21, 1–19, doi:10.3390/ijms21155175.
    17. Tarín, J.J. Potential effects of age-associated oxidative stress on mammalian oocytes/embryos. Mol. Hum. Reprod. 1996, 2, 717–724.
    18. Ngô, C.; Chéreau, C.; Nicco, C.; Weill, B.; Chapron, C.; Batteux, F. Reactive oxygen species controls endometriosis progression. Am. J. Pathol. 2009, 175, 225–234, doi:10.2353/ajpath.2009.080804.
    19. Zhang, J.; Bao, Y.; Zhou, X.; Zheng, L. Polycystic ovary syndrome and mitochondrial dysfunction. Reprod. Biol. Endocrinol. 2019, 17, 1–15.
    20. Tiosano, D.; Mears, J.A.; Buchner, D.A. Mitochondrial Dysfunction in Primary Ovarian Insufficiency. Endocrinology 2019, 160, 2353–2366.
    21. Lampiao, F. Free radicals generation in an in vitro fertilization setting and how to minimize them . World J. Obstet. Gynecol. 2012, 1, 29, doi:10.5317/wjog.v1.i3.29.
    22. Van Montfoort, A.P.A.; Arts, E.G.J.M.; Wijnandts, L.; Sluijmer, A.; Pelinck, M.-J.; Land, J.A.; Van Echten-Arends, J. Reduced oxygen concentration during human IVF culture improves embryo utilization and cumulative pregnancy rates per cycle. Hum. Reprod. Open 2020, 2020, hoz036, doi:10.1093/hropen/hoz036.
    23. Will, M.A.; Clark, N.A.; Swain, J.E. Biological pH buffers in IVF: Help or hindrance to success. J. Assist. Reprod. Genet. 2011, 28, 711–724, doi:10.1007/s10815-011-9582-0.
    24. Cobo, A.; Bellver, J.; Domingo, J.; Pérez, S.; Crespo, J.; Pellicer, A.; Remohí, J. New options in assisted reproduction technology: The Cryotop method of oocyte vitrification. RBMO 2008, 17, 68–72, doi:10.1016/S1472-6483(10)60295-7.
    25. Chronopoulou, E.; Harper, J.C. IVF culture media: Past, present and future. Hum. Reprod. Update 2015, 21, 39–55, doi:10.1093/humupd/dmu040.
    26. Bentov, Y.; Hannam, T.; Jurisicova, A.; Esfandiari, N.; Casper, R.F. Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF-ICSI Treatment. Clin. Med. Insights Reprod. Heal. 2014, 8, CMRH.S14681, doi:10.4137/cmrh.s14681.
    27. Ochiai, A.; Kuroda, K.; Ikemoto, Y.; Ozaki, R.; Nakagawa, K.; Nojiri, S.; Takeda, S.; Sugiyama, R. Influence of resveratrol supplementation on IVF–embryo transfer cycle outcomes. Reprod. Biomed. Online 2019, 39, 205–210, doi:10.1016/j.rbmo.2019.03.205.
    28. Eryilmaz, O.G.; Devran, A.; Sarikaya, E.; Aksakal, F.N.; Mollamahmutoğlu, L.; Cicek, N. Melatonin improves the oocyte and the embryo in IVF patients with sleep disturbances, but does not improve the sleeping problems. J. Assist. Reprod. Genet. 2011, 28, 815–820, doi:10.1007/s10815-011-9604-y.
    29. Showell, M.G.; Mackenzie-Proctor, R.; Jordan, V.; Hart, R.J. Antioxidants for female subfertility. Cochrane Database Syst. Rev. 2017, 2017, 1–154, doi:10.1002/14651858.CD007807.pub3.
    30. Showell, M.G.; Mackenzie-Proctor, R.; Jordan, V.; Hart, R.J. Antioxidants for female subfertility. Cochrane Database Syst. Rev. 2020, 2020, doi:10.1002/14651858.CD007807.pub4.
    31. Arcaniolo, D.; Favilla, V.; Tiscione, D.; Pisano, F.; Bozzini, G.; Creta, M.; Gentile, G.; Fabris, F.M.; Pavan, N.; Veneziano, I.A.; et al. Is there a place for nutritional supplements in the treatment of idiopathic male infertility? Arch. Ital. di Urol. e Androl. 2014, 86, 164–170.
    32. Quadros Gomes, B.A.; Bastos Silva, J.P.; Rodrigues Romeiro, C.F.; dos Santos, S.M.; Rodrigues, C.A.; Gonçalves, P.R.; Sakai, J.T.; Santos Mendes, P.F.; Pompeu Varela, E.L.; Monteiro, M.C. Neuroprotective mechanisms of resveratrol in Alzheimer’s disease: Role of SIRT1. Oxid. Med. Cell. Longev. 2018, 2018, doi:10.1155/2018/8152373.
    33. Zhao, X.; Zhang, M.; Li, C.; Jiang, X.; Su, Y.; Zhang, Y. Benefits of Vitamins in the Treatment of Parkinson’s Disease. Oxid. Med. Cell. Longev. 2019, 2019, doi:10.1155/2019/9426867.
    34. Reiter, R.J.; Tan, D.X.; Rosales-Corral, S.; Galano, A.; Zhou, X.J.; Xu, B. Mitochondria: Central organelles for melatonins antioxidant and anti-Aging actions. Molecules 2018, 23, 1–25, doi:10.3390/molecules23020509.
    35. Yeung, C.K.; Billings, F.T.; Claessens, A.J.; Roshanravan, B.; Linke, L.; Sundell, M.B.; Ahmad, S.; Shao, B.; Shen, D.D.; Ikizler, T.A.; et al. Coenzyme Q10 dose-escalation study in hemodialysis patients: Safety, tolerability, and effect on oxidative stress Dialysis and Transplantation. BMC Nephrol. 2015, 16, 2–9, doi:10.1186/s12882-015-0178-2.
    36. El Refaeey, A.; Selem, A.; Badawy, A. Combined coenzyme Q10 and clomiphene citrate for ovulation induction in clomiphene-citrate-resistant polycystic ovary syndrome. Reprod. Biomed. Online 2014, 29, 119–124, doi:10.1016/j.rbmo.2014.03.011.
    37. Xu, Y.; Nisenblat, V.; Lu, C.; Li, R.; Qiao, J.; Zhen, X.; Wang, S. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: A randomized controlled trial. Reprod. Biol. Endocrinol. 2018, 16, 29, doi:10.1186/s12958-018-0343-0.
    38. Ma, L.; Cai, L.; Hu, M.; Wang, J.; Xie, J.; Xing, Y.; Shen, J.; Cui, Y.; Liu, X.J.; Liu, J. Coenzyme Q10 supplementation of human oocyte in vitro maturation reduces postmeiotic aneuploidies. Fertil. Steril. 2020, 114, 331–337, doi:10.1016/j.fertnstert.2020.04.002.
    39. Kile, R.; Logsdon, D.M.; Nathanson, C.; McCormick, S.; Schoolcraft, W.B.; Krisher, R.L. Mitochondrial support of embryos from women of advanced maternal age during ART. Fertil. Steril. 2020, 114, e122, doi:10.1016/j.fertnstert.2020.08.363.
    40. Liu, M.J.; Sun, A.G.; Zhao, S.G.; Liu, H.; Ma, S.Y.; Li, M.; Huai, Y.X.; Zhao, H.; Liu, H. Bin Resveratrol improves in vitro maturation of oocytes in aged mice and humans. Fertil. Steril. 2018, 109, 900–907, doi:10.1016/j.fertnstert.2018.01.020.
    41. Bahramrezaie, M.; Amidi, F.; Aleyasin, A.; Saremi, A.T.; Aghahoseini, M.; Brenjian, S.; Khodarahmian, M.; Pooladi, A. Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: A triple-blind randomized clinical trial. J. Assist. Reprod. Genet. 2019, 36, 1701–1712, doi:10.1007/s10815-019-01461-6.
    42. Takasaki, A.; Nakamura, Y.; Tamura, H.; Shimamura, K.; Morioka, H. Melatonin as a new drug for improving oocyte quality. Reprod. Med. Biol. 2003, 2, 139–144.
    43. Tamura, H.; Takasaki, A.; Miwa, I.; Taniguchi, K.; Maekawa, R.; Asada, H.; Taketani, T.; Matsuoka, A.; Yamagata, Y.; Shimamura, K.; et al. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J. Pineal Res. 2008, 44, 280–287, doi:10.1111/j.1600-079X.2007.00524.x.
    44. Batioǧlu, A.S.; Şahin, U.; Grlek, B.; Öztrk, N.; Ünsal, E. The efficacy of melatonin administration on oocyte quality. Gynecol. Endocrinol. 2012, 28, 91–93, doi:10.3109/09513590.2011.589925.
    45. Kim, M.K.; Park, E.A.; Kim, H.J.; Choi, W.Y.; Cho, J.H.; Lee, W.S.; Cha, K.Y.; You Kim, S.; Lee, D.R.; Yoon, T.K. Does supplementation of in-vitro culture medium with melatonin improve IVF outcome in PCOS. Reprod. Biomed. Online 2013, 26, 22–29, doi:10.1016/j.rbmo.2012.10.007.
    46. Fernando, S.; Wallace, E.M.; Vollenhoven, B.; Lolatgis, N.; Hope, N.; Wong, M.; Lawrence, M.; Lawrence, A.; Russell, C.; Leong, K.; et al. Melatonin in assisted reproductive technology: A pilot double-blind randomized placebo-controlled clinical trial. Front. Endocrinol. 2018, 9, 545, doi:10.3389/fendo.2018.00545.
    47. Espino, J.; Macedo, M.; Lozano, G.; Ortiz, Á.; Rodríguez, C.; Rodríguez, A.B.; Bejarano, I. Impact of melatonin supplementation in women with unexplained infertility undergoing fertility treatment. Antioxidants 2019, 8, 338, doi:10.3390/antiox8090338.
    48. Gaskins, A.J.; Afeiche, M.C.; Wright, D.L.; Toth, T.L.; Williams, P.L.; Gillman, M.W.; Hauser, R.; Chavarro, J.E. Dietary folate and reproductive success among women undergoing assisted reproduction. Obstet. Gynecol. 2014, 124, 801–809, doi:10.1097/AOG.0000000000000477.
    49. Murto, T.; Skoog Svanberg, A.; Yngve, A.; Nilsson, T.K.; Altmäe, S.; Wånggren, K.; Salumets, A.; Stavreus-Evers, A. Folic acid supplementation and IVF pregnancy outcome in women with unexplained infertility. Reprod. Biomed. Online 2014, 28, 766–772, doi:10.1016/j.rbmo.2014.01.017.
    50. Griesinger, G.; Franke, K.; Kinast, C.; Kutzelnigg, A.; Riedinger, S.; Kulin, S.; Kaali, S.G.; Feichtinger, W. Ascorbic Acid Supplement During Luteal Phase in IVF. J. Assist. Reprod. Genet. 2002, 19, 164–168.
    51. Crha, I.; Hrubá, D.; Ventruba, P.; Fiala, J.; Totušek, J.; Višňová, H. Ascorbic acid and infertility treatment. Cent. Eur. J. Public Health 2003, 11, 63–67.
    52. Lu, X.; Wu, Z.; Wang, M.; Cheng, W. Effects of vitamin C on the outcome of in vitro fertilization–embryo transfer in endometriosis: A randomized controlled study. J. Int. Med. Res. 2018, 46, 4624–4633, doi:10.1177/0300060518786918.
    53. Bahadori, M.H.; Sharami, S.H.; Fakor, F.; Milani, F.; Pourmarzi, D.; Dalil-Heirati, S.F. Level of Vitamin E in Follicular Fluid and Serum and Oocyte Morphology and Embryo Quality in Patients Undergoing IVF Treatment. J. Fam. Reprod. Heal. 2017, 11, 74.
    54. Fatemi, F.; Mohammadzadeh, A.; Sadeghi, M.R.; Akhondi, M.M.; Mohammadmoradi, S.; Kamali, K.; Lackpour, N.; Jouhari, S.; Zafadoust, S.; Mokhtar, S.; et al. Role of vitamin E and D3 supplementation in Intra-Cytoplasmic Sperm Injection outcomes of women with polycystic ovarian syndrome: A double blinded randomized placebo-controlled trial. Clin. Nutr. ESPEN 2017, 18, 23–30, doi:10.1016/j.clnesp.2017.01.002.
    55. Özkaya, M.O.; Nazıroğlu, M.; Barak, C.; Berkkanoglu, M. Effects of multivitamin/mineral supplementation on trace element levels in serum and follicular fluid of women undergoing in vitro fertilization (IVF). Biol. Trace Elem. Res. 2011, 139, 1–9, doi:10.1007/s12011-010-8637-x.
    56. Youssef, M.A.F.M.; Abdelmoty, H.I.; Elashmwi, H.A.; Abduljawad, E.M.; Elghamary, N.; Magdy, A.; Mohesen, M.N.; Abdella, R.M.A.; Bar, M.A.; Gouda, H.M.; et al. Oral antioxidants supplementation for women with unexplained infertility undergoing ICSI/IVF: Randomized controlled trial. Hum. Fertil. 2014, 18, 38–42, doi:10.3109/14647273.2014.927595.